Johnson & Johnson MedTech has announced a strategic co-promotion agreement with Pacira BioSciences, Inc. to enhance its Early Intervention portfolio for osteoarthritis of the knee. This collaboration introduces ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), a non-opioid treatment option aimed at alleviating pain associated with osteoarthritis. The partnership aims to advance orthopaedic care by offering non-surgical solutions earlier in the treatment process, addressing the needs of over 30 million affected adults in the United States. The agreement also includes initiatives to increase professional education and patient engagement, focusing on providing effective, longer-lasting pain relief and improving patient outcomes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.